George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,114.00
Bid: 12,112.00
Ask: 12,116.00
Change: 126.00 (1.05%)
Spread: 4.00 (0.033%)
Open: 12,254.00
High: 12,256.00
Low: 12,052.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

More to come as bear capitulation drives recent risk rally

Mon, 19th Jun 2023 10:48

STOXX 600 down 0.5%

*

Major indices in the red

*

U.S. markets closed for Juneteenth holiday

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

MORE TO COME AS BEAR CAPITULATION DRIVES RECENT RISK RALLY (0948 GMT)

Stock markets are taking a breather on Monday after a rally which has seen the DAX close at a record high on Friday, the Nasdaq surge almost 38% year-to-date and the S&P 500 enter a technical bull market.

Ben Laidler, global markets strategist at eToro, says positive fundamentals have driven the rally but poor investor sentiment has also been important.

"We are now in a positive ‘pain trade’, as previously bearish investors capitulate and chase stocks higher," Laidler writes.

"Poor sentiment has had two benefits, protecting on the downside and is now magnifying the upside."

Laidler says this "bear capitulation" can be powerful and last for a while before sentiment becomes too bullish and the dynamic reverses.

Meanwhile, Jefferies chief financial economist Europe Mohit Kumar says they are retaining their small long position in risky assets amid the recent buoyant mood.

"There is little in terms of data between now and the U.S. payrolls which would dent the recent optimism," Kumar says.

"We still struggle to see significant upside from current levels, but believe that the path of least resistance is for modestly higher risky assets."

(Samuel Indyk)

CAUTIOUS START FOR EUROPE (0811 GMT)

European equity markets are taking a breather on Monday after a strong performance last week that saw Germany's DAX close at a record high and broader European shares notch their biggest weekly gain in two months.

The pan-European benchmark STOXX 600 index is down around 0.6%, while the DAX , CAC 40 and FTSE 100 are down 0.3%-0.6%.

"Investors are lacking Monday motivation today, as caution returns amid worries about global growth," says Susannah Streeter, head of money and markets, Hargreaves Lansdown.

"European indices have opened lower ... as investors mull what's ahead for the path of interest rates, given the stubbornness of inflation, while concerns persist about China's recovery losing steam."

Shares in Franco-German lab supplies maker Sartorius are down around 13% after the company cut its margin and sales forecast.

Aerospace and Defence stocks are a rare bright spot, as attention falls on Paris, where the world's largest aviation trade show is kicking off, with airlines going into the event with growing demand expectations.

Here's your opening snapshot:

(Samuel Indyk)

MONDAY BLUES FOR EUROPEAN FUTURES (0635 GMT)

European equity futures are struggling on Monday, consolidating after major indices clocked their biggest weekly gain in two months last week.

Euro STOXX 50 futures are down 0.6%. Futures on Germany's DAX are also losing 0.6% after the index closed at a

record high

on Friday.

With a U.S. market holiday and a lack of major data releases in Europe, focus is falling on geopolitics as U.S. Secretary of State Antony Blinken wraps up his

trip to China

, where a meeting with Chinese President Xi Jinping might be in the offing.

In company news, AstraZeneca will be in focus after the Financial Times reported the drugmaker is drafting a plan to

spin off its China business.

Attention will also be on aerospace and defence names, as the week-long Paris Airshow kicks off.

(Samuel Indyk)

READY FOR MORE RATE HIKES, AND ONE CUT (0554 GMT)

It's been predictably subdued in Asia as a U.S. holiday provides a convenient excuse for stocks to consolidate recent hefty gains before a bevy of central bank meetings this week. Most indices are down, with the Nikkei off modestly having climbed 22% over a 10-week streak to hit 33-year highs.

S&P 500 futures were also flat having risen for five weeks in a row, while the NASDAQ has notched eight weeks of gains. Those rallies are narrowly based, though, with just nine large-cap stocks making up 30% of the S&P 500. It's hard to call the index a "diversified" investment any more.

Markets are watching U.S. Secretary of State Antony Blinken's visit to Beijing, though you know expectations are low when it's newsworthy that a Chinese diplomat deigned to shake his hand.

Among currencies, the yen downtrend remains alive and well as the euro and dollar both make new highs, albeit by just a few ticks. Further losses look likely unless and until the Bank of Japan takes another step toward tightening, which many Western analysts see as possible in July. Governor Kazuo Ueda, however, seemed to set a high bar for a move last week by saying his outlook for inflation would have to shift "sharply" to justify a move.

The coming week is also jammed with central bank action, led by China on Tuesday where prime loan rates are expected to be cut by 10 basis points. That might be pushing on string given mortgage rates have already fallen markedly and lower rates only eat into the return on household savings. Markets are really hanging on for more fiscal stimulus to revive growth, as it has so often in the past.

Federal Reserve Chair Jerome Powell appears before lawmakers on Wednesday and Thursday and may again try to convince markets that two more quarter-point rate hikes are really, honestly, cross-my-heart likely.

Futures seem unimpressed with just 21 basis points of tightening priced in by September, though one final hike in July is rated as a decent 70% chance.

In contrast, markets are baying for the Bank of England to hike when it meets on Thursday, the only question being by 25 or 50 basis points. Futures lean toward the smaller move to 4.75% but also have rates rising to at least 5.75% given stubborn inflation and surging wages.

Gilt yields have already hit 15-year highs, causing havoc in the UK mortgage market and lifting the government's already astronomical borrowing costs.

Rate hikes are also expected in Norway and Switzerland this week, perhaps by 50 basis points, though that will likely pale in comparison to Turkey's central bank as some analysts see rates rising from the current 8% to as much as 25%.

Key developments that could influence markets on Monday:

- ECB board member Isabel Schnabel, ECB Vice President Luis de Guindos and ECB chief economist Philip Lane are all speaking

- U.S. stock and bond markets are closed, while the NAHB housing market index for June is due

(Wayne Cole)

More News
Today 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
Today 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
Today 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
Today 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more
25 Apr 2024 07:43

LONDON BRIEFING: Miner Anglo American eyes rival BHP takeover

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.